Loading clinical trials...
Loading clinical trials...
A Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging, Phase 2b Study to Investigate the Efficacy of ESN364 in Postmenopausal Women Suffering From Vasomotor Symptoms (Hot Flashes)
Conditions
Interventions
Fezolinetant
Placebo
Locations
51
United States
Research Site
Anniston, Alabama, United States
Research Site
Birmingham, Alabama, United States
Research Site
Phoenix, Arizona, United States
Research Site
Los Angeles, California, United States
Research Site
Oceanside, California, United States
Research Site
Panorama City, California, United States
Start Date
July 19, 2017
Primary Completion Date
September 19, 2018
Completion Date
September 19, 2018
Last Updated
November 26, 2024
NCT07472881
NCT05188027
NCT06691178
NCT06826755
NCT07022925
NCT06813261
Lead Sponsor
Astellas Pharma Global Development, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions